ALPMY Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 21:59):

Stats
Dagens volum	257 679
Gjennomsnittsvolum	332 679
Markedsverdi	18.00B
EPS	$0 ( 2024-04-25 )
Last Dividend	$0.220 ( 2021-09-28 )
Next Dividend	$0 ( N/A )
P/E	502.00
ATR14	$0.0100 (0.10%)

Volum Korrelasjon

Lang: 0.06 (neutral)

Kort: -0.12 (neutral)

Signal:(40.359) Neutral

Astellas Pharma Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Astellas Pharma Inc. Korrelasjon - Valuta/Råvare

-0.12
( neutral )

-0.07
( neutral )

0.00
( neutral )

-0.08
( neutral )

-0.29
( neutral )

0.28
( neutral )

Astellas Pharma Inc. Økonomi

Annual	2024
Omsetning:	$1 603.67B
Bruttogevinst:	$1 212.37B (75.60 %)
EPS:	$9.50

FY	2024
Omsetning:	$1 603.67B
Bruttogevinst:	$1 212.37B (75.60 %)
EPS:	$9.50

FY	2023
Omsetning:	$1 518.62B
Bruttogevinst:	$1 191.83B (78.48 %)
EPS:	$54.24

FY	2022
Omsetning:	$1 296.16B
Bruttogevinst:	$1 014.87B (78.30 %)
EPS:	$67.08

Financial Reports:

No articles found.

Astellas Pharma Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Astellas Pharma Inc. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.96 - good (89.56%) | Divividend Growth Potential Score: 5.72 - Stable (14.49%)

Information

First Dividend	$0.192	2021-03-29
Last Dividend	$0.220	2021-09-28
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.412	--
Avg. Dividend % Per Year	0.00%	--
Score	3.22	--
Div. Sustainability Score	8.96
Div.Growth Potential Score	5.72
Div. Directional Score	7.34	--

Next Divdend (Est)
(2024-06-21)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

3.22

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
OSAGY	No Dividend Player	2023-06-16	Annually	0.00%
DAIUF	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
TXHPF	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
JARLF	Ex Dividend Knight	2023-08-17	Semi-Annually	0.00%
BDVSY	Ex Dividend Junior	2023-09-28	Annually	0.00%
RCBC	Ex Dividend Junior	2023-07-31	Quarterly	0.00%
ENGGY	Ex Dividend Knight	2023-07-03	Semi-Annually	0.00%
WBHC	Ex Dividend Junior	2023-06-29	Sporadic	0.00%
LDSCY	Ex Dividend Junior	2023-08-24	Quarterly	0.00%
CCFN	Ex Dividend Knight	2023-08-14	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.00805	1.500	9.84	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00362	1.200	9.88	10.00	[0 - 0.3]
returnOnEquityTTM	0.00817	1.500	-1.020	-1.530	[0.1 - 1]
payoutRatioTTM	9.04	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	0.929	0.800	-0.354	-0.283	[1 - 3]
quickRatioTTM	0.687	0.800	-0.663	-0.530	[0.8 - 2.5]
cashRatioTTM	0.261	1.500	9.66	10.00	[0.2 - 2]
debtRatioTTM	0.258	-1.500	5.70	-8.56	[0 - 0.6]
interestCoverageTTM	14.83	1.000	5.62	5.62	[3 - 30]
operatingCashFlowPerShareTTM	101.14	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	55.12	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.576	-1.500	7.69	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.756	1.000	0.733	0.733	[0.2 - 0.8]
operatingProfitMarginTTM	0.111	1.000	9.78	9.78	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.197	1.000	-0.0162	-0.0162	[0.2 - 2]
assetTurnoverTTM	0.449	0.800	-0.338	-0.271	[0.5 - 2]
Total Score				8.96

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	213.34	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.00817	2.50	-0.656	-1.530	[0.1 - 1.5]
freeCashFlowPerShareTTM	55.12	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.0238	1.500	9.40	0	[0 - 0.4]
operatingCashFlowPerShareTTM	101.14	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	9.04	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	0.421	1.500	-0.525	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.113	1.000	9.67	0	[0.1 - 0.5]
Total Score				5.72

Astellas Pharma Inc.

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.